Weizmann Institute

(Rehovot, Israel)

The Weizmann Institute of Science (WIS) is at the forefront of research and treatment innovation. The collaboration with Steba biotech led to the formation of Steba Laboratories, a research centre that enables the production and rapid targeting of new compounds prior to an in-depth pre-clinical assessment.

The partnership between WEIZMANN and Steba Laboratories has already resulted in numerous projects and represents a new concept in which Steba biotech, in its capacity as an industrial and commercial partner, has access to university-based innovations at an early stage of the research.

This approach enables the early targeting of candidate compounds for different therapy indications. As soon as a candidate compound seems to meet the industrial requirements, the WEIZMANN team proceeds with preliminary pre-clinical studies.

At present, two new families of compounds are being studied: one comprises bacteriochlorophyll conjugates with small molecules containing the RGD tripeptide for tumour targeting and the other comprises cationic molecules. The studies concern colorectal cancer and breast cancer, among others, and are based around the improvement of innate and adaptive immunity.

©2020 by Steba Biotech. Proudly created with Wix.com

Steba biotech ©